Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGXX NASDAQ:GRCE NASDAQ:NBRV NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsGRCEGrace Therapeutics$3.03+1.3%$3.12$1.75▼$4.97$41.35M0.7298,324 shs62,000 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/ANRXPNRx Pharmaceuticals$2.32-7.9%$2.90$1.10▼$6.01$49.92M1.59472,681 shs569,458 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGXXBright Green0.00%0.00%0.00%0.00%-72.95%GRCEGrace Therapeutics+1.34%-6.77%+2.02%+8.60%+302,999,900.00%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%NRXPNRx Pharmaceuticals-7.94%-12.12%-17.44%-11.45%+23.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/AGRCEGrace Therapeutics2.5265 of 5 stars3.50.00.00.02.70.81.3NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANRXPNRx Pharmaceuticals3.1575 of 5 stars3.65.00.00.02.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGXXBright Green 0.00N/AN/AN/AGRCEGrace Therapeutics 3.00Buy$12.00296.04% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ANRXPNRx Pharmaceuticals 3.20Buy$28.501,128.45% UpsideCurrent Analyst Ratings BreakdownLatest BGXX, NBRV, NRXP, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025NRXPNRx PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/19/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.008/11/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.008/4/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.006/20/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.006/6/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$4.60 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00NRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.80) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/AGRCEGrace Therapeutics-$9.57M-$0.86N/AN/AN/AN/A-20.36%-18.09%11/12/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ANRXPNRx Pharmaceuticals-$25.13M-$2.24N/AN/AN/AN/AN/A-550.94%11/13/2025 (Estimated)Latest BGXX, NBRV, NRXP, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NRXPNRx Pharmaceuticals-$0.31-$0.98-$0.67-$0.98N/AN/A8/12/2025Q1 2026GRCEGrace Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/A6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGXXBright GreenN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGXXBright GreenN/A0.010.01GRCEGrace TherapeuticsN/A8.878.87NBRVNabriva Therapeutics0.120.850.52NRXPNRx PharmaceuticalsN/A0.110.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGXXBright Green7.83%GRCEGrace Therapeutics6.08%NBRVNabriva Therapeutics0.27%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipBGXXBright Green62.55%GRCEGrace Therapeutics11.10%NBRVNabriva Therapeutics1.63%NRXPNRx Pharmaceuticals19.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGXXBright Green2191.17 million71.59 millionNo DataGRCEGrace TherapeuticsN/A13.83 million12.29 millionN/ANBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableNRXPNRx Pharmaceuticals219.81 million16.05 millionOptionableBGXX, NBRV, NRXP, and GRCE HeadlinesRecent News About These CompaniesNRx Pharmaceuticals (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track DesignationAugust 28 at 11:34 AM | financial-news.co.ukNRx Pharmaceuticals announces expanded access policy for NRX-100August 27 at 12:16 PM | msn.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)August 27 at 8:03 AM | globenewswire.comNRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old ProblemAugust 27 at 7:15 AM | theglobeandmail.comD. Boral Capital Remains a Buy on NRX Pharmaceuticals (NRXP)August 27 at 2:14 AM | theglobeandmail.comBTIG Sticks to Its Buy Rating for NRX Pharmaceuticals (NRXP)August 27 at 2:14 AM | theglobeandmail.comAnson Funds Management LP Has $2.42 Million Stock Holdings in NRx Pharmaceuticals, Inc. $NRXPAugust 26, 2025 | marketbeat.comNRx Pharmaceuticals price target raised to $25 from $21 at BTIGAugust 25, 2025 | msn.comNRx Pharmaceuticals (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine PreservativeAugust 25, 2025 | financial-news.co.ukNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2025 Earnings Call TranscriptAugust 21, 2025 | msn.comNRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comNRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral CapitalAugust 20, 2025 | americanbankingnews.comAdvancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc ...August 19, 2025 | theglobeandmail.comNRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead ProgramsAugust 19, 2025 | msn.comNrx Pharmaceuticals Faces Financing Hurdles in Strategic Acquisitions of Kadima and Dura MedicalAugust 19, 2025 | msn.comNRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings Report Preview: What to ExpectAugust 19, 2025 | finance.yahoo.comNRx Pharmaceuticals sees cash runway into 2026August 18, 2025 | msn.comWhat To Expect From NRX Pharmaceuticals Inc (NRXP) Q2 2025 EarningsAugust 18, 2025 | finance.yahoo.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and ...August 18, 2025 | gurufocus.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and ...August 18, 2025 | gurufocus.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBGXX, NBRV, NRXP, and GRCE Company DescriptionsBright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.Grace Therapeutics NASDAQ:GRCE$3.03 +0.04 (+1.34%) As of 08/29/2025 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.NRx Pharmaceuticals NASDAQ:NRXP$2.32 -0.20 (-7.94%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.35 +0.03 (+1.08%) As of 08/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
